NO333191B1 - Farmasoytiske sammensetning og kit som omfatter valsartan og spesifikke NEPinhibitorer. - Google Patents

Farmasoytiske sammensetning og kit som omfatter valsartan og spesifikke NEPinhibitorer.

Info

Publication number: NO333191B1
Authority: NO; Norway
Prior art keywords: diabetic; disease; renal; pharmaceutical composition; pharmaceutically acceptable
Prior art date: 2002-01-17

Application number

NO20043380A

Other languages

English (en)

Norwegian (no)

Other versions

NO20043380L (no

Inventor

Randy Lee Webb

Gary Michael Ksander

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-17

Filing date

2004-08-13

Publication date

2013-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO333191(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-13 Application filed by Novartis Ag filed Critical Novartis Ag

2004-10-07 Publication of NO20043380L publication Critical patent/NO20043380L/no

2013-03-25 Publication of NO333191B1 publication Critical patent/NO333191B1/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20043380A 2002-01-17 2004-08-13 Farmasoytiske sammensetning og kit som omfatter valsartan og spesifikke NEPinhibitorer. NO333191B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34966002P	2002-01-17	2002-01-17
PCT/EP2003/000415 WO2003059345A1 (fr)	2002-01-17	2003-01-16	Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep

Publications (2)

Publication Number	Publication Date
NO20043380L NO20043380L (no)	2004-10-07
NO333191B1 true NO333191B1 (no)	2013-03-25

Family

ID=23373410

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20043380A NO333191B1 (no)	2002-01-17	2004-08-13	Farmasoytiske sammensetning og kit som omfatter valsartan og spesifikke NEPinhibitorer.
NO2016009C NO2016009I2 (no)	2002-01-17	2016-05-18	Sakubitril/valsartan, inkludert farmasøytisk akseptable salter derav

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2016009C NO2016009I2 (no)	2002-01-17	2016-05-18	Sakubitril/valsartan, inkludert farmasøytisk akseptable salter derav

Country Status (29)

Country	Link
EP (1)	EP1467728B1 (fr)
JP (2)	JP4820056B2 (fr)
KR (2)	KR100984939B1 (fr)
CN (2)	CN102091330B (fr)
AT (1)	ATE370732T1 (fr)
AU (1)	AU2003206738C1 (fr)
BE (1)	BE2016C025I2 (fr)
BR (2)	BR122018015003B8 (fr)
CA (1)	CA2472399C (fr)
CO (1)	CO5600999A2 (fr)
CY (2)	CY1106959T1 (fr)
DE (1)	DE60315795T2 (fr)
DK (1)	DK1467728T3 (fr)
EC (1)	ECSP045190A (fr)
ES (1)	ES2290429T3 (fr)
FR (1)	FR16C0019I2 (fr)
HU (1)	HUS1600024I1 (fr)
IL (2)	IL162661A0 (fr)
LU (1)	LU93074I2 (fr)
MX (1)	MXPA04006917A (fr)
NL (1)	NL300811I2 (fr)
NO (2)	NO333191B1 (fr)
NZ (1)	NZ533968A (fr)
PL (1)	PL212318B1 (fr)
PT (1)	PT1467728E (fr)
RU (1)	RU2334513C3 (fr)
SI (1)	SI1467728T1 (fr)
WO (1)	WO2003059345A1 (fr)
ZA (1)	ZA200405117B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA06014448A (es) *	2004-06-23	2007-03-01	Solvay Pharm Gmbh	Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y antagonista del receptor at1.
PT2033629E (pt) *	2004-12-24	2013-01-24	Krka	Composição farmacêutica sólida que compreende valsartan
MY146830A (en) *	2005-02-11	2012-09-28	Novartis Ag	Combination of organic compounds
WO2007045663A2 (fr) *	2005-10-19	2007-04-26	Novartis Ag	Combinaison de composes organiques
WO2007051007A2 (fr) *	2005-10-28	2007-05-03	Novartis Ag	Combinaison de composes organiques
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (fr) *	2006-03-10	2007-09-20	Novartis Ag	Combinaison de composes organiques
CZ300801B6 (cs) *	2006-06-07	2009-08-12	Helvetia Pharma A.S.	Kompozice s valsartanem v pevných lékových formách
KR101580067B1 (ko)	2007-01-12	2015-12-23	노파르티스 아게	5-바이페닐-4-아미노-2-메틸 펜탄산의 제조 방법
GB0708507D0 (en)	2007-05-02	2007-06-13	Queen Mary & Westfield College	Substituted phosphonates and their use
EP3067043B1 (fr)	2007-11-06	2022-11-30	Novartis AG	Compositions pharmaceutiques basées sur des superstructures d'antagoniste/bloqueur du récepteur de l'angiotensine (arb) et de l'inhibiteur de l'endopeptidase neutre (nep)
CN101774941A (zh)	2009-01-13	2010-07-14	浙江九洲药业股份有限公司	2-酰基氨基-3-联苯基丙酸的制备及拆分方法
EP2435402B1 (fr)	2009-05-28	2016-04-13	Novartis AG	Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
CN103896796B (zh)	2009-05-28	2016-04-27	诺华股份有限公司	作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
RU2588572C2 (ru)	2010-08-23	2016-07-10	Новартис Аг	Способ получения промежуточных соединений для получения ингибиторов nep
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
ES2879550T3 (es) *	2012-08-24	2021-11-22	Novartis Ag	Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
CU24330B1 (es)	2013-02-14	2018-03-13	Novartis Ag	Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
US9102635B2 (en)	2013-02-14	2015-08-11	Novartis Ag	Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
CN104230865B (zh) *	2013-06-13	2018-01-09	上海翰森生物医药科技有限公司	联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
DK3038654T3 (da)	2013-08-26	2020-02-03	Novartis Ag	Ny anvendelse
WO2015030711A1 (fr)	2013-08-26	2015-03-05	Novartis Ag	Nouvelle utilisation
CN106458857A (zh) *	2014-08-27	2017-02-22	上海翰森生物医药科技有限公司	AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (fr) *	2014-09-04	2016-03-10	Concert Pharmaceuticals, Inc.	Sacubitril deutérisé
CN106414416B (zh) *	2014-09-09	2020-03-27	上海翰森生物医药科技有限公司	结晶型ARB-NEPi复合物及其制备方法和应用
CN105503760A (zh) *	2014-10-10	2016-04-20	上海翰森生物医药科技有限公司	结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
WO2016074651A1 (fr)	2014-11-14	2016-05-19	Zentiva, K.S.	Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
WO2016086798A1 (fr) *	2014-12-03	2016-06-09	上海翰森生物医药科技有限公司	Acide libre cristallin d'inhibiteur de l'endopeptidase neutre (nep), polymorphe de sel de calcium de celui-ci, leur procédé de préparation et leurs applications
PL3229799T3 (pl) *	2014-12-08	2019-05-31	Crystal Pharmatech Co Ltd	Krystaliczne postacie supramolekularnego kompleksu trisodowego zawierającego walsartan i AHU-377 i ich sposoby
CN105693543B (zh) *	2014-12-15	2018-08-10	四川海思科制药有限公司	沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) *	2015-04-19	2015-08-12	浙江巨泰药业有限公司	一种抗心衰药物组合物及其制备方法
CN106138069A (zh) *	2015-04-21	2016-11-23	刘春丽	作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
EP4212152B1 (fr)	2015-05-11	2025-04-30	Novartis AG	Schéma posologique du sacubutril-valsartan pour le traitement de l'insuffisance cardiaque systolique chronique
US20180140579A1 (en)	2015-05-29	2018-05-24	Novartis Ag	Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (fr)	2015-07-08	2017-01-12	Novartis Ag	Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
WO2017012600A1 (fr)	2015-07-20	2017-01-26	Zentiva, K.S.	Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
CN106397248A (zh) *	2015-08-03	2017-02-15	深圳信立泰药业股份有限公司	一种lcz696结晶粉末及其制备方法
EP3355880A1 (fr)	2015-08-28	2018-08-08	Novartis AG	Nouvelle utilisation
WO2017036420A1 (fr) *	2015-09-06	2017-03-09	常州方楠医药技术有限公司	Composition pharmaceutique contenant du valsartan et du sacubitril, et procédé de préparation associé
CN105348209B (zh) *	2015-12-09	2017-12-26	浙江天宇药业股份有限公司	一种抗心衰药lcz696的制备方法
EP3386945A1 (fr)	2015-12-11	2018-10-17	Zentiva, K.S.	Formes solides d'ester éthylique d'acide (2r,4s)-5-(biphényl-4-yl)-4-[(3-carboxypropionyl)amino]-2-méthylpentanoïque, ses sels et son procédé de préparation
ES3036922T3 (en)	2016-02-03	2025-09-25	Novartis Ag	New use of a combination of sacubitril and valsartan
HK1256865A1 (zh)	2016-02-03	2019-10-04	Novartis Ag	有机化合物的盖伦制剂
CN109803657B (zh)	2016-10-08	2022-07-29	武汉朗来科技发展有限公司	药物组合物
WO2018211479A1 (fr)	2017-05-19	2018-11-22	Lupin Limited	Compositions stabilisées d'inhibiteurs de l'angiotensine ii et d'inhibiteurs de l'endopeptidase neutre, et leur procédé de préparation
WO2019008485A1 (fr) *	2017-07-06	2019-01-10	Mankind Pharma Ltd	Composition pharmaceutique à dose fixe à base de valsartan et de sacubitril
MX391562B (es)	2017-07-28	2025-03-21	Synthon Bv	Composicion farmaceutica que comprende sacubitril y valsartan
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh) *	2018-03-09	2022-03-22	武汉朗来科技发展有限公司	药物制剂及其应用
EP3840746A1 (fr)	2018-08-23	2021-06-30	Novartis AG	Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque
WO2020039394A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Nouvelles combinaisons de médicaments
KR20200020746A (ko)	2020-02-07	2020-02-26	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
WO2021158084A1 (fr) *	2020-02-07	2021-08-12	보령제약 주식회사	Composé hybride et son procédé de préparation
KR20210101164A (ko)	2020-02-07	2021-08-18	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
KR20210120560A (ko)	2020-03-27	2021-10-07	주식회사 유영제약	고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko)	2020-12-24	2022-07-01	주식회사 보령	사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
WO2024136185A1 (fr)	2022-12-20	2024-06-27	주식회사 티에치팜	Composition pharmaceutique pour la prévention ou le traitement d'une maladie cardiovasculaire, comprenant un inhibiteur du cotransporteur sodium-glucose-2 et un bloqueur du récepteur de l'angiotensine ii
EP4640213A1 (fr)	2022-12-20	2025-10-29	THPharm Corp.	Préparation pharmaceutique orale comprenant un inhibiteur du cotransporteur de sodium-glucose de type 2 et un bloqueur du récepteur de l'angiotensine ii
CN116687921A (zh) *	2023-06-14	2023-09-05	宁波大学	沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1256692A (en) *	1991-02-06	1992-09-07	Schering Corporation	Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) *	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (fr) *	1995-02-08	1996-08-09	James R. Powell	Traitement de l'hypertension et de l'insuffisance cardiaque globale
JP2003533440A (ja) *	2000-04-03	2003-11-11	ブリストル−マイヤーズスクイブカンパニー	隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
NZ540748A (en) *	2000-06-22	2007-04-27	Novartis Ag	An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1
BR0112665A (pt) *	2000-07-19	2003-06-24	Novartis Ag	Sais
US6777443B2 (en) *	2001-05-15	2004-08-17	Novartis Ag	Dipeptide derivatives

2003
- 2003-01-16 DK DK03704413T patent/DK1467728T3/da active
- 2003-01-16 SI SI200331029T patent/SI1467728T1/sl unknown
- 2003-01-16 WO PCT/EP2003/000415 patent/WO2003059345A1/fr not_active Ceased
- 2003-01-16 CA CA2472399A patent/CA2472399C/fr not_active Expired - Lifetime
- 2003-01-16 NZ NZ533968A patent/NZ533968A/en not_active IP Right Cessation
- 2003-01-16 EP EP03704413A patent/EP1467728B1/fr not_active Expired - Lifetime
- 2003-01-16 KR KR1020047011124A patent/KR100984939B1/ko not_active Ceased
- 2003-01-16 CN CN201110029600.7A patent/CN102091330B/zh not_active Expired - Lifetime
- 2003-01-16 JP JP2003559507A patent/JP4820056B2/ja not_active Expired - Lifetime
- 2003-01-16 AT AT03704413T patent/ATE370732T1/de active
- 2003-01-16 ES ES03704413T patent/ES2290429T3/es not_active Expired - Lifetime
- 2003-01-16 AU AU2003206738A patent/AU2003206738C1/en active Active
- 2003-01-16 PL PL369773A patent/PL212318B1/pl unknown
- 2003-01-16 PT PT03704413T patent/PT1467728E/pt unknown
- 2003-01-16 BR BR122018015003A patent/BR122018015003B8/pt not_active IP Right Cessation
- 2003-01-16 RU RU2004125178A patent/RU2334513C3/ru active
- 2003-01-16 MX MXPA04006917A patent/MXPA04006917A/es active IP Right Grant
- 2003-01-16 IL IL16266103A patent/IL162661A0/xx unknown
- 2003-01-16 BR BRPI0306907A patent/BRPI0306907B8/pt active IP Right Grant
- 2003-01-16 KR KR1020107010521A patent/KR20100057704A/ko not_active Ceased
- 2003-01-16 CN CNA038022680A patent/CN1615134A/zh active Pending
- 2003-01-16 DE DE60315795T patent/DE60315795T2/de not_active Expired - Lifetime
2004
- 2004-06-21 IL IL162661A patent/IL162661A/en active Protection Beyond IP Right Term
- 2004-06-28 ZA ZA2004/05117A patent/ZA200405117B/en unknown
- 2004-07-14 EC EC2004005190A patent/ECSP045190A/es unknown
- 2004-08-06 CO CO04076723A patent/CO5600999A2/es active IP Right Grant
- 2004-08-13 NO NO20043380A patent/NO333191B1/no not_active IP Right Cessation
2007
- 2007-10-25 CY CY20071101386T patent/CY1106959T1/el unknown
2011
- 2011-05-25 JP JP2011116928A patent/JP2011207898A/ja not_active Withdrawn
2016
- 2016-05-17 FR FR16C0019C patent/FR16C0019I2/fr active Active
- 2016-05-18 CY CY2016013C patent/CY2016013I2/el unknown
- 2016-05-18 BE BE2016C025C patent/BE2016C025I2/nl unknown
- 2016-05-18 LU LU93074C patent/LU93074I2/fr unknown
- 2016-05-18 NL NL300811C patent/NL300811I2/nl unknown
- 2016-05-18 NO NO2016009C patent/NO2016009I2/no unknown
- 2016-05-18 HU HUS1600024C patent/HUS1600024I1/hu unknown

Also Published As

Publication number	Publication date
KR100984939B1 (ko)	2010-10-01
CY2016013I1 (el)	2016-10-05
AU2003206738B2 (en)	2006-12-21
PL212318B1 (pl)	2012-09-28
FR16C0019I2 (fr)	2017-12-08
MXPA04006917A (es)	2004-12-06
DE60315795T2 (de)	2008-06-05
CN1615134A (zh)	2005-05-11
RU2334513C2 (ru)	2008-09-27
LU93074I2 (fr)	2016-07-18
BE2016C025I2 (fr)	2022-05-17
KR100984939B9 (ko)	2024-07-17
JP4820056B2 (ja)	2011-11-24
BR122018015003B1 (pt)	2018-11-21
ECSP045190A (es)	2004-08-27
NL300811I2 (fr)	2016-07-27
RU2004125178A (ru)	2005-06-10
RU2334513C3 (ru)	2017-10-24
WO2003059345A1 (fr)	2003-07-24
KR20100057704A (ko)	2010-05-31
ATE370732T1 (de)	2007-09-15
CN102091330B (zh)	2015-04-08
BR122018015003B8 (pt)	2021-07-27
BRPI0306907B1 (pt)	2018-10-30
BRPI0306907B8 (pt)	2021-05-25
CO5600999A2 (es)	2006-01-31
CN102091330A (zh)	2011-06-15
NZ533968A (en)	2006-10-27
BR0306907A (pt)	2004-12-21
IL162661A0 (en)	2005-11-20
SI1467728T1 (sl)	2008-02-29
EP1467728A1 (fr)	2004-10-20
CA2472399C (fr)	2012-02-21
NO2016009I1 (no)	2016-05-18
PT1467728E (pt)	2007-11-14
JP2005514441A (ja)	2005-05-19
ZA200405117B (en)	2005-08-31
NO2016009I2 (no)	2016-05-18
JP2011207898A (ja)	2011-10-20
FR16C0019I1 (fr)	2016-06-24
NO20043380L (no)	2004-10-07
IL162661A (en)	2010-11-30
ES2290429T3 (es)	2008-02-16
AU2003206738A1 (en)	2003-07-30
CA2472399A1 (fr)	2003-07-24
AU2003206738C1 (en)	2020-01-30
CY2016013I2 (el)	2016-10-05
EP1467728B1 (fr)	2007-08-22
PL369773A1 (en)	2005-05-02
CY1106959T1 (el)	2012-01-25
DE60315795D1 (de)	2007-10-04
KR20040078127A (ko)	2004-09-08
DK1467728T3 (da)	2007-12-27
HUS1600024I1 (hu)	2016-06-28

Legal Events

Date	Code	Title	Description
2016-05-30	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: SAKUBITRIL/VALSARTAN, INKLUDERT FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/15/1058 20151126 Spc suppl protection certif: 2016009 Filing date: 20160518
2018-04-09	SPCB	Board of appeal decision concerning a supplementary protection certificate (spc)	Free format text: KLAGENEMNDAS AVGJOERELSE AV 2018.03.20: 1 KLAGEN TAS TIL FOELGE. 2 UTVIDET BESKYTTELSESSERTIFIKAT MEDDELES FOR SOEKNAD NR. 2016009. Spc suppl protection certif: 2016009 Effective date: 20180320
2018-05-07	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: SAKUBITRIL/VALSARTAN, INKLUDERT FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/15/1058 20151126 Spc suppl protection certif: 2016009 Filing date: 20160518 Extension date: 20280116
2023-02-13	MK1K	Patent expired

Publication	Publication Date	Title
NO333191B1 (no)	2013-03-25	Farmasoytiske sammensetning og kit som omfatter valsartan og spesifikke NEPinhibitorer.
WO2007106708A3 (fr)	2007-12-27	Combinaison de composes organiques
LU92000I2 (fr)	2012-07-16	Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables
LU92992I2 (fr)	2016-05-09	Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables
AR040017A1 (es)	2005-03-09	Combinacion de compuestos organicos
BR0317384A (pt)	2005-11-16	Combinações de valsartan com inibidores de cox-2